Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study**Sponsored by the Canadian Fertility Research Association and funded by a grant-in-aid from Berlen Laboratories Limited, Canada.††The following collaborators participated in this study: Peter Garner, M.D., University of Ottawa; Barbara Cruckshank, M.D., University of Western Ontario; Youssef Ainmelk, M.D., University of Sherbrooke; Togas Tulandi, M.D., McGill University; Nacia Faure, M.D., Laval University; Arthur Leader, M.D., University of Calgary; Timothy Rowe, M.D., University of British Columbia; and Jerald Bain, M.D., University of Toronto.
-
Published:1986-12
Issue:6
Volume:46
Page:1015-1020
-
ISSN:0015-0282
-
Container-title:Fertility and Sterility
-
language:en
-
Short-container-title:Fertility and Sterility
Author:
Belisle Serge,Love Edgar J.
Subject
Obstetrics and Gynecology,Reproductive Medicine
Reference19 articles.
1. Female hirsutism: pathophysiological considerations and therapeutic implications;Biffignandi;Endocr Rev,1984
2. Behandlung des hirsutismus cyproterone acetat. Dtsch Med Wochenschr 94:829, 1969;Hammerstein;Translated to German Med Monthly,1969
3. Pharmacology of antiandrogens;Neumann,1980
4. Aspects of androgen dependent events as studied by antiandrogens;Newmann;Recent Prog Horm Res,1970
5. The evaluation of the role of androgens in hirsutism and the use of a new antiandrogen cyproterone acetate for therapy;Ismail;J Clin Endocrinol Metab,1974
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献